Novozymes Company Top Insiders

NVZMF Stock  USD 58.86  0.09  0.15%   
Novozymes employs about 6.4 K people. The company is managed by 33 executives with a total tenure of roughly 229 years, averaging almost 6.0 years of service per executive, having 195.09 employees per reported executive. Examination of Novozymes' management performance can provide insight into the company performance.
Peder Nielsen  CEO
CEO and Pres
Henrik Gurtler  Chairman
Chairman of the Board
  
Check out Correlation Analysis to better understand how to build diversified portfolios, which includes a position in Novozymes AS B. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in population.

Novozymes Management Team Effectiveness

The company has return on total asset (ROA) of 0.1062 % which means that it generated a profit of $0.1062 on every $100 spent on assets. This is way below average. Similarly, it shows a return on equity (ROE) of 0.2789 %, meaning that it generated $0.2789 on every $100 dollars invested by stockholders. Novozymes' management efficiency ratios could be used to measure how well Novozymes manages its routine affairs as well as how well it operates its assets and liabilities.

Novozymes Workforce Comparison

Novozymes AS B is considered to be number one stock in number of employees category among related companies. The total workforce of Specialty Chemicals industry is now estimated at about 718,526. Novozymes maintains roughly 6,438 in number of employees contributing less than 1% to equities listed under Specialty Chemicals industry.
The company has Profit Margin (PM) of 0.21 %, which maeans that even a very small decline in it revenue will erase profits resulting in a net loss. This is way below average. Similarly, it shows Operating Margin (OM) of 0.26 %, which suggests for every 100 dollars of sales, it generated a net operating income of $0.26.

Novozymes AS B Benchmark Summation

Operator
The output start index for this execution was zero with a total number of output elements of sixty-one. Novozymes AS B Price Series Summation is a cross summation of Novozymes price series and its benchmark/peer.

Novozymes Notable Stakeholders

A Novozymes stakeholder refers to an individual interested in an outcome of the business. Different stakeholders have different interests, and companies such as Novozymes often face trade-offs trying to please all of them. Novozymes' stakeholders can have a positive or negative influence on the entity's direction, and there are a lot of executives involved in getting Novozymes' stock to the level that pleases all shareholders. Keeping track of the stakeholders is a great way to stay on top of things affecting its ongoing price.
Peder NielsenCEO and PresProfile
Henrik GurtlerChairman of the BoardProfile
Anders LundExecutive Vice President Household Care & Technical IndustriesProfile
Tina FanoeExecutive Vice President Agriculture & BioenergyProfile
Prisca HavranekKosicekCFOProfile
Benny LoftCFO and Executive VPProfile
Thomas VidebaekCOO and Executive VP of Bus. Devel.Profile
Thomas NagyExecutive VP of Supply OperationsProfile
Andrew FordyceExecutive VP of Food and BeveragesProfile
Kasim KutayDirectorProfile
Agnete RaaschouNielsenDirectorProfile
Joergen RasmussenIndependent DirectorProfile
Lena HalskovDirector, Employee RepresentativeProfile
HeinzJuergen BertramIndependent DirectorProfile
Anders KnudsenDirector, Employee RepresentativeProfile
Lena OlvingIndependent DirectorProfile
Mathias UhlenIndependent DirectorProfile
Patricia MalarkeyDirectorProfile
Kim StrattonDirectorProfile
Lena HolskovDirector, Employee RepresentativeProfile
Lars GreenDirectorProfile
Lars KoepplerIndependent Director, Employee RepresentativeProfile
Tobias BjorklundHead of Investor RelationsProfile
Ester BaigetPres CEOProfile
Pedro FernandesHead AmericaProfile
Tue MicheelsenVP MarketingProfile
Sebastian SderbergVP AcquisitionsProfile
Martin RiiseHead of Investor RelationsProfile
Graziela MalucelliSupply OperationsProfile
Per FalholtConsultantProfile
Morten RasmussenSustainability PeopleProfile
Thomas BomhoffHead of Investor RelationsProfile
MSc MScEx CFOProfile

About Novozymes Management Performance

The success or failure of an entity such as Novozymes AS B often depends on how effective the management is. Novozymes management team is responsible for propelling the future growth in the right direction and administering and controlling the business activities and accounting for the results. Ineffective management usually contributes to failure in the company's future performance for all stakeholders equally, but most importantly, for investors. So it is important to measure the effectiveness of Novozymes management before purchasing its stock. In many ways, it's all about finding the answer to one important question - Are they doing the right thing right now? How would we assess whether the Novozymes management is utilizing all available resources in the best possible way? Also, how well is the company doing relative to others in its sector and the market as a whole? The answer can be found by analyzing a few important fundamental indicators such as return on assets and return on equity.
Novozymes AS produces and sells industrial enzymes, microorganisms, and probiotics in Europe, the Middle East, Africa, North America, the Asia Pacific, and Latin America. The company was founded in 1925 and is headquartered in Bagsvaerd, Denmark. NOVOZYMES is traded on OTC Exchange in the United States.
The data published in Novozymes' official financial statements usually reflect Novozymes' business processes, product offerings, services, and other fundamental events. But there are other numbers, ratios, or fundamental indicators derived from these statements that are easier to understand and visualize within the underlying realities that drive quantitative information of Novozymes AS B. For example, before you start analyzing numbers published by Novozymes accountants, it's critical to develop an understanding of what Novozymes' liquidity, profitability, and earnings quality are in the context of the Basic Materials space in which it operates.
Please note, the presentation of Novozymes' financial position, as portrayed in its financial statements, is often influenced by management's estimates, judgments, and sometimes even manipulations. In the best case, Novozymes' management is honest, while the outside auditors are strict and uncompromising. Whatever the case, the imprecision that can be found in Novozymes' accounting process means that the reasonable investor should take a skeptical approach toward the financial statement analysis of Novozymes AS B. Please utilize our Beneish M Score to check the likelihood of Novozymes' management manipulating its earnings.

Novozymes Workforce Analysis

Traditionally, organizations such as Novozymes use manpower efficiency calculations for various incentive schemes, employee appraisal, or as an initiative to improve the processes. However, it can also be used by investors to make long-term investment decisions. The trends in the profit per employee or revenue per employee are measured by net income or revenue divided by the current number of full-time employees over a given time interval. Because workforce needs differ across sectors, these ratios could be used to compare Novozymes within its industry.

Novozymes Manpower Efficiency

Return on Novozymes Manpower

Revenue Per Employee2.7M
Revenue Per Executive531.9M
Net Income Per Employee571K
Net Income Per Executive111.4M
Working Capital Per Employee414.1K
Working Capital Per Executive80.8M
Check out Correlation Analysis to better understand how to build diversified portfolios, which includes a position in Novozymes AS B. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in population.
You can also try the Equity Analysis module to research over 250,000 global equities including funds, stocks and ETFs to find investment opportunities.

Complementary Tools for Novozymes Pink Sheet analysis

When running Novozymes' price analysis, check to measure Novozymes' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Novozymes is operating at the current time. Most of Novozymes' value examination focuses on studying past and present price action to predict the probability of Novozymes' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Novozymes' price. Additionally, you may evaluate how the addition of Novozymes to your portfolios can decrease your overall portfolio volatility.
Funds Screener
Find actively-traded funds from around the world traded on over 30 global exchanges
Pattern Recognition
Use different Pattern Recognition models to time the market across multiple global exchanges
Insider Screener
Find insiders across different sectors to evaluate their impact on performance
ETF Categories
List of ETF categories grouped based on various criteria, such as the investment strategy or type of investments
Technical Analysis
Check basic technical indicators and analysis based on most latest market data
Portfolio Center
All portfolio management and optimization tools to improve performance of your portfolios
Sign In To Macroaxis
Sign in to explore Macroaxis' wealth optimization platform and fintech modules
Bond Analysis
Evaluate and analyze corporate bonds as a potential investment for your portfolios.
Piotroski F Score
Get Piotroski F Score based on the binary analysis strategy of nine different fundamentals
Sync Your Broker
Sync your existing holdings, watchlists, positions or portfolios from thousands of online brokerage services, banks, investment account aggregators and robo-advisors.
FinTech Suite
Use AI to screen and filter profitable investment opportunities
Portfolio Analyzer
Portfolio analysis module that provides access to portfolio diagnostics and optimization engine
Please note, there is a significant difference between Novozymes' value and its price as these two are different measures arrived at by different means. Investors typically determine if Novozymes is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Novozymes' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.